Second-Quarter 2020 Results and Highlights:<\/p>\n
FORT MYERS, FL \/ ACCESSWIRE \/ July 28, 2020 \/ NeoGenomics, Inc. (NASDAQ:NEO) (the \"Company\"), a leading provider of cancer-focused genetics testing services, today announced its second-quarter results for the period ended June 30, 2020.<\/p>\n
\"As expected, second quarter financial results were challenging due to the global COVID-19 crisis, which reduced both revenue and earnings,\" said Douglas M. VanOort, Chairman and CEO of NeoGenomics.<\/p>\n
\"Even in the midst of this pandemic, we made several strategic moves and invested in our business. We fortified our balance sheet with a successful offering of both common stock and convertible securities, we strategically invested in Inivata for access to liquid biopsy and minimal residual disease testing capabilities, we launched a suite of liquid biopsy tests, we moved forward with investments to further globalize our Pharma Services business, and we built and operationalized a high-capacity COVID-19 testing laboratory. We believe these investments will deliver both near-term and long-term growth, and that we exited the second quarter in a stronger competitive position for the future.\"<\/p>\n
Second-Quarter Results<\/p>\n
Consolidated revenue for the second quarter of 2020 was $87 million, a decrease of 14% over the same period in 2019. Clinical Services revenue decreased year-over-year by 17% to $74 million driven by a clinical test volume(1) decrease of 18%. Average revenue per clinical test (\"revenue per test\") remained stable at $351. Pharma Services revenue grew by 3% to $13 million compared to the second quarter of 2019, primarily due to the January 10, 2020 acquisition of the Oncology Division assets of Human Longevity, Inc. (\"HLI - Oncology\"). While disruptions in volume stemming from the COVID-19 pandemic reduced growth in both Divisions, there was steady improvement throughout the quarter.<\/p>\n
Gross profit was $28.0 million, a decline of 42.8%, compared to the second quarter of 2019. This reduction was the result of the combined effect of lower test volume due to the impact of the COVID-19 pandemic and our decision to retain employees.<\/p>\n
Operating expenses increased by $2 million, or 5%, compared to the second quarter of 2019, reflecting investments in informatics, growth initiatives and costs associated with the integration of HLI - Oncology.<\/p>\n
Net loss for the quarter was $7 million compared to net income of $2 million for the second quarter of 2019.<\/p>\n
Adjusted EBITDA(2) was negative $7 million for the quarter compared to positive $15 million in the second quarter of 2019. Adjusted Net (Loss) Income(2) was a loss of $4 million compared to income of $7 million in the second quarter of 2019.<\/p>\n
Cash and cash equivalents, including restricted cash, was $331 million and days sales outstanding (\"DSO\") was 92 days at the end of the second quarter of 2020 due to the impact of COVID-19 and the distribution of revenue.<\/p>\n
(1) Clinical tests exclude requisitions, tests, revenue and costs for Pharma Services and COVID-19 Polymerase Chain Reaction (\"PCR\") tests.<\/p>\n
(2) The Company has provided adjusted financial information that has not been prepared in accordance with GAAP, including Adjusted EBITDA, Adjusted Net (Loss) Income, and Adjusted Diluted EPS. Each of these measures is defined in the section of this report entitled \"Use of Non-GAAP Financial Measures.\" See also the tables reconciling such measures to their closest GAAP equivalent.<\/p>\n
Conference Call<\/p>\n
The Company has scheduled a webcast and conference call to discuss their first quarter results on Tuesday, July 28, 2020 at 8:30 AM EDT. Interested investors should dial (844) 602-0380 (domestic) and (862) 298-0970 (international) at least five minutes prior to the call. A replay of the conference call will be available until 8:30 AM EDT on August 11, 2020, and can be accessed by dialing (877) 481-4010 (domestic) and (919) 882-2331 (international). The playback conference ID Number is 35578. The webcast may be accessed under the Investor Relations section of our website at http:\/\/www.neogenomics.com<\/a>. An archive of the webcast will be available until 08:30 AM EDT on October 28, 2020.<\/p>\n About NeoGenomics, Inc.<\/p>\n NeoGenomics, Inc. specializes in cancer genetics testing and information services. The Company provides one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company's Pharma Services Division serves pharmaceutical clients in clinical trials and drug development.<\/p>\n Headquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA certified laboratories in Fort Myers and Tampa, Florida; Aliso Viejo, Carlsbad, Fresno and San Diego, California; Houston, Texas; Atlanta, Georgia; Nashville, Tennessee; and CAP accredited laboratories in Rolle, Switzerland, and Singapore. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and pharmaceutical firms in Europe and Asia. For additional information about NeoGenomics, visit http:\/\/www.neogenomics.com\/<\/a><\/p>\n Forward Looking Statements<\/p>\n Certain information contained in this press release constitutes forward-looking statements for purposes of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995. These forward looking statements involve a number of risks and uncertainties that could cause actual future results to differ materially from those anticipated in the forward-looking statements as the result of the Company's ability to continue gaining new customers, respond to the effects of the COVID-19 outbreak, offer new types of tests, integrate its acquisitions and otherwise implement its business plan, as well as additional factors discussed under the heading \"Risk Factors\" and elsewhere in the Company's Annual Report on Form 10-K filed with the SEC on February 28, 2020. As a result, this press release should be read in conjunction with the Company's periodic filings with the SEC. In addition, it is the Company's practice to make information about the Company available by posting copies of its Company Overview Presentation from time to time on the Investor Relations section of its website at http:\/\/ir.neogenomics.com\/<\/a>.<\/p>\n Forward-looking statements represent the Company's estimates only as of the date such statements are made (unless another date is indicated) and should not be relied upon as representing the Company's estimates as of any subsequent date. While the Company may elect to update forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, even if its estimates change.<\/p>\n For further information, please contact:<\/p>\n NeoGenomics, Inc.<\/p>\n William Bonello Director, Investor Relations (239) 690-4238 (w) (239) 284-4314 (m) bill.bonello@neogenomics.com<\/a><\/p>\n NeoGenomics, Inc. CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands)<\/p>\n ASSETS<\/p>\n Cash and cash equivalents<\/p>\n Accounts receivable, net<\/p>\n Inventories<\/p>\n Other current assets<\/p>\n Total current assets<\/p>\n Property and equipment (net of accumulated depreciation of $80,143 and $68,809 respectively)<\/p>\n Operating lease right-of-use assets<\/p>\n Intangible assets, net<\/p>\n Goodwill<\/p>\n Restricted cash, non-current<\/p>\n Prepaid lease asset<\/p>\n Investment in non-consolidated affiliate<\/p>\n Other assets<\/p>\n TOTAL ASSETS<\/p>\n LIABILITIES AND STOCKHOLDERS' EQUITY<\/p>\n Accounts payable and other current liabilities<\/p>\n Short-term portion of financing obligations<\/p>\n Short-term portion of operating leases<\/p>\n Total current liabilities<\/p>\n Long-term portion of financing obligations<\/p>\n Long-term portion of operating leases<\/p>\n Convertible senior notes, net<\/p>\n Deferred income tax liability, net<\/p>\n Other long-term liabilities<\/p>\n Total long-term liabilities<\/p>\n TOTAL LIABILITIES<\/p>\n TOTAL STOCKHOLDERS' EQUITY<\/p>\n TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY<\/p>\n NeoGenomics, Inc. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (In thousands, except per share amounts) <\/p>\n NET REVENUE:<\/p>\n Clinical Services<\/p>\n Pharma Services<\/p>\n Total revenue<\/p>\n COST OF REVENUE<\/p>\n GROSS PROFIT<\/p>\n Operating expenses:<\/p>\n General and administrative<\/p>\n Research and development<\/p>\n Sales and marketing<\/p>\n Total operating expenses<\/p>\n (LOSS) INCOME FROM OPERATIONS<\/p>\n Interest expense, net<\/p>\n Other (income) expense, net<\/p>\n Loss on extinguishment of debt<\/p>\n Loss on termination of cash flow hedge<\/p>\n (Loss) income before taxes<\/p>\n Income tax (benefit) expense<\/p>\n NET (LOSS) INCOME<\/p>\n NET (LOSS) INCOME PER SHARE<\/p>\n Basic<\/p>\n Diluted<\/p>\n WEIGHTED AVERAGE COMMON SHARES OUTSTANDING<\/p>\n Basic<\/p>\n Diluted<\/p>\n NeoGenomics, Inc. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (In thousands)<\/p>\n CASH FLOWS FROM OPERATING ACTIVITIES<\/p>\n Net loss<\/p>\n Adjustments to reconcile net income to net cash provided by operating activities:<\/p>\n Depreciation<\/p>\n Loss on disposal of assets<\/p>\n Loss on debt extinguishment<\/p>\n Loss on termination of cash flow hedge<\/p>\n Amortization of intangibles<\/p>\n Amortization of debt issue costs<\/p>\n Amortization of convertible debt discount<\/p>\n Non-cash stock-based compensation<\/p>\n Non-cash operating lease expense<\/p>\n Changes in assets and liabilities, net<\/p>\n Net cash (used in) provided by operating activities<\/p>\n CASH FLOWS FROM INVESTING ACTIVITIES<\/p>\n Purchases of property and equipment<\/p>\n Business acquisition<\/p>\n Acquisition working capital adjustment<\/p>\n Investment in non-consolidated affiliate<\/p>\n <\/p>\n Excerpt from: Second-Quarter 2020 Results and Highlights: FORT MYERS, FL \/ ACCESSWIRE \/ July 28, 2020 \/ NeoGenomics, Inc. (NASDAQ:NEO) (the \"Company\"), a leading provider of cancer-focused genetics testing services, today announced its second-quarter results for the period ended June 30, 2020. \"As expected, second quarter financial results were challenging due to the global COVID-19 crisis, which reduced both revenue and earnings,\" said Douglas M Continue reading
\nNeoGenomics Reports Revenue of $87 Million in the Second Quarter amid COVID-19 Pandemic - Stockhouse<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"